“Looking Toward Best-in-Class” KRASG12C Therapy

The development of second-generation covalent “off”-state KRAS^G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with good tolerability, in non–small cell lung cancer as well as in colorectal cancer, against which the activity of first-generation inhibitors has been underwhelming.